Illuminavs.Revvity
ILMN vs RVTY · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Illumina is about 2.2× larger than Revvity by market cap; Illumina trades at the lower P/E (34.7 vs 55.1); year to date, Illumina leads (+70.2% vs +27.1%).
Side by side
| ILMN | RVTY | |
|---|---|---|
| Market cap | $28.7B | $13.1B |
| Price | $224.99 | $124.84 |
| Today | +0.8% | +1.5% |
| Return YTD | +70.2% | +27.1% |
| Return 1Y | +119.3% | +30.6% |
| P/E | 34.7 | 55.1 |
| P/S | 6.4 | 4.5 |
| P/B | 10.1 | 1.8 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
IlluminaILMN
DNA sequencing machines and the reagents they consume, for research and clinical genomics.
Full ILMN profile →RevvityRVTY
Newborn and genetic screening is the clinical end of the business; the rest supplies reagents and software to research laboratories.
Full RVTY profile →More ILMN & RVTY comparisons
Other head-to-heads in the Life science tools segment.
See where ILMN and RVTY sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →